High-Risk, Non-Muscle-Invasive Bladder Cancer: Recent Updates to KEYNOTE-057 Trial Data

home / investigator-perspectives / high-risk-non-muscle-invasive-bladder-cancer-recent-updates-to-keynote-057-trial-data

Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses recent data from KEYNOTE-057 presented at the 2023 American Urological Association (AUA) Annual Meeting, and offers clinical insights on treatment paradigms for non-muscle-invasive bladder cancer.

Eric A. Singer, MD, MA, FACS, an expert on bladder cancer

EP. 1: Treatment Options for Non-Muscle-Invasive Bladder Cancer

Eric A. Singer, MD, MA, FACS
May 22nd 2023

Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses the use of Bacillus Calmette-Guerin (BCG) as a first-line therapy for non-muscle-invasive bladder cancer (NMIBC), and reviews subsequent treatment options for patients with high-risk NMIBC who are found to be unresponsive to BCG.

Eric A. Singer, MD, MA, FACS, an expert on bladder cancer

EP. 2: KEYNOTE-057: Pembrolizumab in Patients With High-Risk NMIBC

Eric A. Singer, MD, MA, FACS
May 22nd 2023

An overview of the study design, patient populations, and eligibility of the KEYNOTE-057 trial, which studied pembrolizumab in patients with high-risk NMIBC.

Eric A. Singer, MD, MA, FACS, an expert on bladder cancer

EP. 3: Clinical Implications of Recent KEYNOTE-057 Data

Eric A. Singer, MD, MA, FACS
May 29th 2023

An expert on non-muscle-invasive bladder cancer discusses how data on Cohort B of KEYNOTE-057 presented at the AUA 2023 meeting might impact treatment strategies.

Eric A. Singer, MD, MA, FACS, an expert on bladder cancer

EP. 4: Clinical Pearls and Future of Bladder Cancer Treatment

Eric A. Singer, MD, MA, FACS
May 29th 2023

Eric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.

© 2024 MJH Life Sciences

All rights reserved.